Target intelligence / Profile preview

Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3)

Target
CREB3L3
Molecular classification
Transcription factor, Basic leucine zipper protein, AMP-dependent transcription factor family
01

Overview

Cyclic AMP-responsive element-binding protein 3-like protein 3 is a transcription factor of the basic leucine zipper family predominantly localized to the endoplasmic reticulum membrane. Upon ER stress or cyclic AMP stimulation, it undergoes regulated proteolysis, releasing an active fragment that translocates to the nucleus to control gene expression related to lipid and glucose metabolism, iron homeostasis, acute inflammatory response, and hepatic circadian regulation. It acts in concert with nuclear receptors and coactivators (such as PPARα) to promote fatty acid oxidation, ketogenesis, and expression of FGF21, thereby exerting systemic metabolic effects and mitigating insulin resistance and hypertriglyceridemia. CREB3L3 is implicated as a therapeutic target for metabolic disorders, including hyperlipidemia, diabetes, atherosclerosis, and hepatocellular carcinoma.

Other names
CREBHCREB-HHYST1481HYTG2cAMP responsive element binding protein 3 like 3Processed cyclic AMP-responsive element-binding protein 3-like protein 3cAMP-responsive element-binding protein, hepatic-specificCREB3L3Cyclic AMP-responsive element-binding protein 3-like protein 3
02

Mechanism of action

Transcriptional activation or inhibition of downstream metabolic and inflammatory genes, including synergy with ATF6 and PPARα

03

Biological functions

Regulation of glucose metabolismTriglyceride metabolismLipid metabolismAcute inflammatory responseIron homeostasisHepcidin expressionEndoplasmic reticulum stress responseCellular stress responseCircadian rhythm modulationActivation of phase response genesFatty acid oxidationKetogenesisHepatic gluconeogenesis
04

Disease associations

HypertriglyceridemiaHepatocellular carcinomaMetabolic disease (e.g., diabetes, insulin resistance)AtherosclerosisLiver steatosisAcute inflammation
05

Safety considerations

Modulation risks include dysregulation of lipid/glucose metabolismpossible increased risk for metabolic syndromeliver diseasesand inflammatory responses
06

Interacting drugs

No approved drugs specifically targeting CREB3L3 reported to date; experimental modulation through signaling pathways such as CB1R (Cannabinoid receptor 1) may impact CREB3L3 activity
07

Biomarkers

Plasma triglyceride concentrationsHepcidin levelsFGF21 levels

Beyond the preview

Go deeper on Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call